Alcidion has completed a fundraising
December 2021 — Alcidion Group Ltd. (ASX:ALC) has raised funds to acquire Silverlink PCS Software Limited.
Alcidion is transforming healthcare with smart, intuitive technology solutions that provide real-time clinical decision support. The group integrates with EMR providers and assists doctors and nurses, covering functions such as streamlining patient journeys, smart analytics to help with clinical decisions, improving patient safety and productivity amongst clinical staff through messaging applications, and data capture and interpretation.
Our role in the transaction
Oaklins’ team in Australia acted as joint underwriter, joint lead manager and joint bookrunner, alongside Canaccord Genuity (Australia) Ltd. The team has supported Alcidion in raising over US$70 million across three transactions, along with assisting shareholders to realize value via on-market trading, over the past three years.
Talk to the deal team
Related deals
Mattina Holding has sold a 5% stake in Gens Aurea via accelerated bookbuild
Mattina Holding S.A. (DVC Partners) has sold a 5% stake in Italian company Gens Aurea S.p.A. through an accelerated bookbuild, raising approximately US$69.96 million.
Learn moreVeremark has completed a secondary share sale
Veremark, the global workplace trust company, has completed an employee and early investor secondary share sale, on the London Stock Exchange’s (LSE) Private Securities Market (PSM), valuing the company at over US$133 million in enterprise value. Crowdcube, Europe’s leading private market liquidity platform, managed the transaction.
Learn moreKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn more